---
canonical_url: https://www.stockexpertai.com/earnings/tmo
last_updated: 2026-05-09T17:40:28.218Z
---

# Thermo Fisher Scientific Inc. (TMO) Q4 FY2026 Earnings Preview

> This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T17:40:27.784Z. Educational tool, not investment advice.

---

## Quick Summary

| Field | Value | Source |
|---|---|---|
| Price | $465.00 (▼ -2.01%) | fmp:quote |
| Market Cap | $172.8B | fmp:profile |
| 52w range | $385.46 – $643.99 | fmp:quote |
| Earnings | Wed 22 Jul | fmp:earnings-history |
| EPS estimate | $5.75 (+7% YoY) | fmp:earnings-estimate |
| Revenue estimate | $11.7B | fmp:earnings-estimate |
| Beat streak | 8/4 | fmp:earnings-history |
| Rating | B (overall 3/5) | fmp:ratings |
| Analyst median target | $650 (+39.8% upside) | fmp:price-target-consensus |
| MoonshotScore | 47/100 | derived |
| Council | 4/6 bullish | derived |
| Munger verdict | Undervalued | derived |

## Thermo Fisher Scientific Inc. — Q4 FY2026 Expectations

Q4 consensus: revenue <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$11.7B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>, EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$5.75</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>. 8 consecutive quarters of beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>.

## Quick Take

**Score:** B · **Stance:** BUY · **Council:** 4/6 · **Moonshot:** 47

= MoonshotScore <strong>47</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="9-pillar formula">[9-pillar formula]</sup> + Council <strong>4/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="6-lens rule">[6-lens rule]</sup>. Form 4: 0 transactions<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>.

## Watchlist (5 metrics)

### 1. Q1 Organic Revenue Growth

Thermo Fisher's organic revenue growth in Q1 was 1%.

> "On the top line, Q1 reported revenue grew 6% year-over-year. The components of our reported revenue change included 1% organic growth, a 3% contribution from acquisitions and a 2% tailwind from foreign exchange."
> — James Meyer, Investor Focus · Q1 FY2026

### 2. Bioproduction Growth

The Life Sciences Solutions segment's reported revenue increased 13% due to strong growth in the bioproduction business.

> "In Life Sciences Solutions, Q1 reported revenue increased 13% versus the prior year quarter and organic revenue growth was 1%. The growth in this segment was led by our bioproduction business, which had another quarter of excellent organic growth."
> — James Meyer, Investor Focus · Q1 FY2026

### 3. Fy26 Guidance Increase

Thermo Fisher is raising its full year revenue and adjusted EPS guidance, incorporating the positive impact of Clario and the strong first quarter earnings performance.

> "We are raising our guidance for the full year on the top and bottom line, incorporating the positive impact of Clario and the strong first quarter earnings performance."
> — Marc Casper, Expectation / Guide · Q1 FY2026

### 4. Clario Acquisition Impact

The acquisition of Clario increased Thermo Fisher's 2026 revenue guidance by $900 million and added $0.32 of adjusted EPS net of financing costs.

> "This incorporates the acquisition of Clario, which increased our 2026 revenue guidance by $900 million and added $0.32 of adjusted EPS net of financing costs."
> — James Meyer, Investor Focus · Q1 FY2026

### 5. Capital Deployment

Thermo Fisher deployed $3.2 billion of capital to shareholders in Q1 through $3 billion of share buybacks and approximately $160 million of dividends.

> "In Q1, we also deployed $3.2 billion of capital to shareholders through $3 billion of share buybacks and approximately $160 million of dividends."
> — James Meyer, Investor Focus · Q1 FY2026


## MoonshotScore Pillars

| Pillar | Score | Level | Evidence |
|---|---|---|---|
| Revenue Growth | 1.0 | weak | Q1 vs Q2: growth slowing (+1.4%, below threshold) |
| Gross Margin | 4.0 | medium | Q1: average margin (40.7%) |
| Operating Leverage | 2.0 | weak | op margin healthy (16.9%) |
| Cash Runway | 10.0 | strong | FCF very strong ($0.8B, 2.2× CapEx) |
| R&D Intensity | 3.0 | weak | average R&D (3.1%) |
| Price Momentum | 4.0 | medium | RSI 40.1 weak momentum, 50d below |
| News Sentiment | 9.0 | strong | strong buy consensus (92%) |

**Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7-Lens)

| Name | Stance | Context |
|---|---|---|
| Ray Dalio | bull | macro · target upside +39.8% |
| Ken Griffin | bear | flow · 50d MA below |
| Jim Simons | neutral | quant · RSI 40 |
| Klarman | bull | value · target upside +39.8% |
| Buffett | bull | quality · ROE score 4/5 |
| Munger | bull | valuation · target upside +39.8% |

**Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## Munger Lens

- **Verdict:** Undervalued
- **Financial Health:** Moderate
- **Margin of Safety:** Strong
- **Interest Coverage:** Adequate
- **ROIC vs WACC:** Healthy

**Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## Technical Levels

- **RSI(14):** 40.1 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az
- **50d MA:** $491 — hisse %5.2 altında — kısa vadeli direnç
- **200d MA:** $528 — hisse %11.9 altında — uzun vadeli baskı
- **Volume (10d):** +80%

## Past Performance (4 Quarters)

| Quarter | EPS Actual | EPS Estimate | Result | Reaction |
|---|---|---|---|---|
| Q2 FY25 | $5.36 | $5.23 | BEAT | +1.8% |
| Q3 FY25 | $5.79 | $5.50 | BEAT | +0.8% |
| Q4 FY25 | $6.57 | $6.45 | BEAT | -2.3% |
| Q1 FY26 | $5.44 | $5.25 | +3.6% EPS | +0.6% |

Q1 (April 23, 2026): EPS $5.44 vs $5.25 est<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, +3.6% beat. D+1 movement: +0.6%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>. Decline despite beat — market reacted to guidance, not numbers.

## 3 Scenarios

### Scenario A · Beat
**Q4 EPS > $5.75 + CapEx discipline**

Threshold: EPS > $5.75<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>.

Target: Break above median target $650<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>; high target $750<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> upper bound.

### Scenario B · In-Line
**EPS ≈ $5.75 + CapEx < $376.0M**

Threshold: EPS ≈ $5.75<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>, Q4 CapEx < $376.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>.

Target: Consolidation in the band between current $465<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> and median $650<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup>.

### Scenario C · Miss
**EPS < $5.58 or CapEx ≥ $376.0M**

Threshold: EPS < $5.58<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>.

Target: Current $465 below SMA200 $528<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>, if rejection continues, $449<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> support activates.

## Risk Notes

### Primary segment below threshold
Q1: EPS $5.44 vs $5.25 beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, stock +0.6% D+1<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>.

### Backlog concentration
No RPO/backlog concentration disclosed in Q1 earnings call.

### Insider trading
Form 4 data is marked in the table — this page does not generate assumptions for this stock.

| Executive | Action | Amount | Date |
|---|---|---|---|


**Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26

### CapEx shock
Q1 CapEx $376.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>. Q1 op margin 16.9%<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — this level in Q4 is sensitive to CapEx revision risk.

## Wall Street Consensus

- **Median target:** $650 (+39.8% upside vs current $465)
- **High / Low:** $750 / $600
- **Buy / Hold / Sell:** 24 / 2 / 0
- **Analyst count:** 3 (last quarter), 66 all-time

## Additional Transcript Insights

### 1. fy26_guidance_increase

**Claim:** Thermo Fisher is raising its full year revenue and adjusted EPS guidance, incorporating the positive impact of Clario and the strong first quarter earnings performance.

**Evidence (transcript):** "We are raising our guidance for the full year on the top and bottom line, incorporating the positive impact of Clario and the strong first quarter earnings performance."

**Numbers:** 6%, 8%

### 2. clario_acquisition_impact

**Claim:** The acquisition of Clario increased Thermo Fisher's 2026 revenue guidance by $900 million and added $0.32 of adjusted EPS net of financing costs.

**Evidence (transcript):** "This incorporates the acquisition of Clario, which increased our 2026 revenue guidance by $900 million and added $0.32 of adjusted EPS net of financing costs."

**Numbers:** 900, 0.32, 2026

### 3. q1_organic_revenue_growth

**Claim:** Thermo Fisher's organic revenue growth in Q1 was 1%.

**Evidence (transcript):** "On the top line, Q1 reported revenue grew 6% year-over-year. The components of our reported revenue change included 1% organic growth, a 3% contribution from acquisitions and a 2% tailwind from foreign exchange."

**Numbers:** 6%, 1%, 3%, 2%

### 4. bioproduction_growth

**Claim:** The Life Sciences Solutions segment's reported revenue increased 13% due to strong growth in the bioproduction business.

**Evidence (transcript):** "In Life Sciences Solutions, Q1 reported revenue increased 13% versus the prior year quarter and organic revenue growth was 1%. The growth in this segment was led by our bioproduction business, which had another quarter of excellent organic growth."

**Numbers:** 13%, 1%

### 5. capital_deployment

**Claim:** Thermo Fisher deployed $3.2 billion of capital to shareholders in Q1 through $3 billion of share buybacks and approximately $160 million of dividends.

**Evidence (transcript):** "In Q1, we also deployed $3.2 billion of capital to shareholders through $3 billion of share buybacks and approximately $160 million of dividends."

**Numbers:** 3.2, 3, 160


---

*Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*